Abeona Therapeutics vs Aquestive Therapeutics
ABEO and AQST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and AQST compare
Aquestive Therapeutics is the larger company, worth 3.1 times as much as Abeona Therapeutics ($464M against $149M).
Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −246% at Abeona Therapeutics.
Abeona Therapeutics scores higher on the StockData Score (8 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | AQST |
|---|---|---|
| Size and price | ||
| Market cap | $149M | $464M |
| Share price | $2.60 | $3.70 |
| Change, 1 year | −41.6% | −31.4% |
| Change, 5 years | −85.8% | −41.9% |
| Beta (5Y) | 1.71 | 1.20 |
| Employees | 226 | 147 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.8× (better) | 8.6× |
| P/B | 1.2× | – |
| FCF yield | −54.8% | −9.9% (better) |
| Fair value | $3.58 | – |
| Margin of safety | 27.4% | – |
| Growth | ||
| Revenue growth (TTM) | – | 22.6% |
| Revenue growth, 5Y average | −10.3% | −0.58% (better) |
| Net income growth (TTM) | −210% | – |
| Profitability | ||
| Gross margin | 67.1% (better) | 67.0% |
| Operating margin | −328% | −97.5% (better) |
| Net margin | −246% | −145% (better) |
| FCF margin | −319% | −85.0% (better) |
| Return on equity | −43.1% | – |
| Financial health | ||
| Debt / equity | 0.12 | – |
| Interest coverage | −25.3× | −4.7× (better) |
| Current ratio | 6.63 | 7.19 (better) |
| Altman Z-score | −4.80 | −3.57 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.9% | 57.4% |
| Held by insiders | 12.3% | 3.2% |
| Insider net buying, 12 months | −$3.5M | −$2.3M (better) |
| Short interest, % of float | 33.7% | 24.1% |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- AQST stock overview
- AQST income statement
- AQST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.